慢性HBV感染人群血清HBsAg清除的影响因素及其临床意义

段金伟; 张鹏; 张婧; 曾婉嘉; 鲁凤民

doi:10.3969/j.issn.1001-5256.2021.07.043

慢性HBV感染人群血清HBsAg清除的影响因素及其临床意义

DOI: 10.3969/j.issn.1001-5256.2021.07.043

段金伟¹,
张鹏²,
张婧³,
曾婉嘉³,
鲁凤民^{3, 4, ,}

1.
郑州大学公共卫生学院流行病学教研室，郑州 450001
2.
天津医科大学研究生院，天津 300070
3.
北京大学基础医学院病原生物学系暨北京大学感染病研究中心，北京 100191
4.
北京大学人民医院肝病研究所，北京 100044

基金项目:

艾滋病和病毒性肝炎等重大传染病防治科技重大专项课题 (2017ZX10202202);

艾滋病和病毒性肝炎等重大传染病防治科技重大专项课题 (2017ZX10202203)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：段金伟、张鹏负责文献资料收集、分析和初稿写作; 张婧、曾婉嘉参与文献资料的分析、整理以及内容补充; 鲁凤民负责项目构思，指导本文写作并最后定稿。

详细信息

通信作者:
鲁凤民，lu.fengmin@hsc.pku.edu.cn

中图分类号: R512.62
计量
- 文章访问数: 700
- HTML全文浏览量: 133
- PDF下载量: 126
- 被引次数: 0
出版历程
- 收稿日期: 2020-11-05
- 录用日期: 2021-01-25
- 出版日期: 2021-07-20

Influencing factors for serum HBsAg clearance in people with chronic hepatitis B virus infection and its clinical significance

1.
Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China
2.
Graduate School of Tianjin Medical University, Tianjin 300070, China
3.
Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China
4.
Hepatology Institute, Peking University People's Hospital, Beijing 100044, China

Research funding:

The National S & T Major Project for Infectious Diseases (2017ZX10202202);

The National S & T Major Project for Infectious Diseases (2017ZX10202203)

摘要

摘要: HBsAg清除能够显著降低慢性乙型肝炎患者终末期肝病及肝癌的发病风险，但无论是自然转归还是抗病毒治疗，HBsAg的清除率都极低。经总结分析慢性HBV感染者HBsAg自发清除和抗病毒治疗清除的影响因素以及清除后的持久性等问题，并对核酸聚合物、免疫调节剂等新型在研药物的HBsAg清除潜力进行综述，以期为今后慢性乙型肝炎的临床治愈提供线索。
- 乙型肝炎 /
- 乙型肝炎表面抗原 /
- 抗病毒药
Abstract: HBsAg clearance can significantly reduce the risk of end-stage liver disease and liver cancer in patients with chronic hepatitis B; however, HBsAg clearance rate is very low, either by spontaneous clearance or antiviral therapy. This article summarizes the influencing factors for spontaneous clearance of HBsAg and HBsAg clearance after antiviral therapy and the durability of HBsAg clearance. In addition, this article reviews the potential of new drugs in development, such as nucleic acid polymers and immunomodulators, in HBsAg clearance, so as to provide clues for the clinical cure of chronic hepatitis B in the future.
- Hepatitis B /
- Hepatitis B Surface Antigens /
- Antiviral Agents

HTML全文

参考文献(46)

[1]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[2]	Chinese Society of Infectious Disease, Chinese Society of Hepatology, Chinese Medical Association. The expert consensus on clinical cure (functional cure) of chronic hepatitis B[J]. J Clin Hepatol, 2019, 35(8): 1693-1701. DOI: 10.3969/j.issn.1001-5256.2019.08.008. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]. 临床肝胆病杂志, 2019, 35(8): 1693-1701. DOI: 10.3969/j.issn.1001-5256.2019.08.008.
[3]	ALAWAD AS, AUH S, SUAREZ D, et al. Durability of spontaneous and treatment-related loss of hepatitis B s antigen[J]. Clin Gastroenterol Hepatol, 2020, 18(3): 700-709. e3. DOI: 10.1016/j.cgh.2019.07.018.
[4]	YIP TC, WONG GL, CHAN HL, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues[J]. J Hepatol, 2019, 70(3): 361-370. DOI: 10.1016/j.jhep.2018.10.014.
[5]	YIP TC, WONG GL, WONG VW, et al. Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients[J]. J Hepatol, 2017. DOI: 10.1016/j.jhep.2017.09.018.[Online ahead of print]
[6]	KIM MA, KIM SU, SINN DH, et al. Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: A nationwide multicentre study[J]. Gut, 2020, 69(12): 2214-2222. DOI: 10.1136/gutjnl-2019-320015.
[7]	ZHOU K, CONTAG C, WHITAKER E, et al. Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: A systematic review and pooled meta-analyses[J]. Lancet Gastroenterol Hepatol, 2019, 4(3): 227-238. DOI: 10.1016/S2468-1253(18)30308-X.
[8]	YEO YH, HO HJ, YANG HI, et al. Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: A systematic review and Meta-analysis[J]. Gastroenterology, 2019, 156(3): 635-646. e9. DOI: 10.1053/j.gastro.2018.10.027.
[9]	NGUYEN LH, HOANG J, NGUYEN NH, et al. Ethnic differences in incidence of hepatitis B surface antigen seroclearance in a real-life multicenter clinical cohort of 4737 patients with chronic hepatitis B infection[J]. Aliment Pharmacol Ther, 2016, 44(4): 390-399. DOI: 10.1111/apt.13709.
[10]	OLIVERI F, SURACE L, CAVALLONE D, et al. Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance[J]. Liver Int, 2017, 37(11): 1622-1631. DOI: 10.1111/liv.13416.
[11]	SHAH PA, KAUR S, SIMONS B, et al. Patterns of HBeAg and HBsAg clearance among a treatment-naive Alaskan Cohort in a long-term observational study[J]. J Viral Hepat, 2020, 27(6): 644-646. DOI: 10.1111/jvh.13271.
[12]	ILUZ-FREUNDLICH D, SAMAD N, MILES D, et al. Spontaneous flares of chronic hepatitis B virus in hepatitis be antigen negative carriers who subsequently clear hepatitis B surface antigen[J]. Dig Dis Sci, 2021, 66(1): 257-262. DOI: 10.1007/s10620-020-06125-5.
[13]	KIM JH, LEE JH, PARK SJ, et al. Factors associated with natural seroclearance of hepatitis B surface antigen and prognosis after seroclearance: A prospective follow-up study[J]. Hepatogastroenterology, 2008, 55(82-83): 578-581. http://www.ncbi.nlm.nih.gov/pubmed/18613411/
[14]	CHU CM, LIAW YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: Appreciably high rates during a long-term follow-up[J]. Hepatology, 2007, 45(5): 1187-1192. DOI: 10.1002/hep.21612.
[15]	CHEN YC, CHU CM, YEH CT, et al. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: A long-term follow-up study[J]. Hepatol Int, 2007, 1(1): 267-273. DOI: 10.1007/s12072-007-5001-0.
[16]	LIU F, WANG XW, CHEN L, et al. Systematic review with meta-analysis: Development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance[J]. Aliment Pharmacol Ther, 2016, 43(12): 1253-1261. DOI: 10.1111/apt.13634.
[17]	LIAW YF. Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(10): 631-641. DOI: 10.1038/s41575-019-0197-8.
[18]	LIU J, LI T, ZHANG L, et al. The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among asian patients with chronic hepatitis B: A systematic review[J]. Hepatology, 2019, 70(3): 1045-1055. DOI: 10.1002/hep.30474.
[19]	LIMOTHAI U, CHUAYPEN N, POOVORAWAN K, et al. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B[J]. J Viral Hepat, 2019, 26(12): 1481-1488. DOI: 10.1111/jvh.13195.
[20]	YAN Y, ALLWEISS L, YANG D, et al. Down-regulation of cell membrane localized NTCP expression in proliferating hepatocytes prevents hepatitis B virus infection[J]. Emerg Microbes Infect, 2019, 8(1): 879-894. DOI: 10.1080/22221751.2019.1625728.
[21]	CAO Z, LIU Y, MA L, et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha[J]. Hepatology, 2017, 66(4): 1058-1066. DOI: 10.1002/hep.29213.
[22]	WONG D, LITTLEJOHN M, EDWARDS R, et al. ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B[J]. Liver Int, 2018, 38(10): 1760-1769. DOI: 10.1111/liv.13716.
[23]	BERG T, SIMON KG, MAUSS S, et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study[J]. J Hepatol, 2017, 67(5): 918-924. DOI: 10.1016/j.jhep.2017.07.012.
[24]	LIAW YF. Hepatitis B flare after cessation of nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B: To retreat or not to retreat[J]. Hepatology, 2021, 73(2): 843-852. DOI: 10.1002/hep.31525.
[25]	PEPPA D, GILL US, REYNOLDS G, et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion[J]. J Exp Med, 2013, 210(1): 99-114. DOI: 10.1084/jem.20121172.
[26]	DONG Y, CHEN H, GAO J, et al. Molecular machinery and interplay of apoptosis and autophagy in coronary heart disease[J]. J Mol Cell Cardiol, 2019, 136: 27-41. DOI: 10.1016/j.yjmcc.2019.09.001.
[27]	WANG H, LUO H, WAN X, et al. TNF-α/IFN-γ profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection[J]. J Hepatol, 2020, 72(1): 45-56. DOI: 10.1016/j.jhep.2019.08.024.
[28]	LOOMBA R, LIANG TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: Current concepts, management strategies, and future directions[J]. Gastroenterology, 2017, 152(6): 1297-1309. DOI: 10.1053/j.gastro.2017.02.009.
[29]	OLIVIERO B, CERINO A, VARCHETTA S, et al. Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections[J]. J Hepatol, 2011, 55(1): 53-60. DOI: 10.1016/j.jhep.2010.10.016.
[30]	ZIMMER CL, RINKER F, HÖNER ZU SIEDERDISSEN C, et al. Increased NK cell function after cessation of long-term nucleos(t)ide analogue treatment in chronic hepatitis B is associated with liver damage and HBsAg loss[J]. J Infect Dis, 2018, 217(10): 1656-1666. DOI: 10.1093/infdis/jiy097.
[31]	PEPPA D, GILL US, REYNOLDS G, et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion[J]. J Exp Med, 2013, 210(1): 99-114. DOI: 10.1084/jem.20121172.
[32]	LI H, ZHAI N, WANG Z, et al. Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection[J]. Gut, 2018, 67(11): 2035-2044. DOI: 10.1136/gutjnl-2017-314098.
[33]	MICHLER T, KOSINSKA AD, FESTAG J, et al. Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice[J]. Gastroenterology, 2020, 158(6): 1762-1775. e9. DOI: 10.1053/j.gastro.2020.01.032.
[34]	NING Q, WU D, WANG GQ, et al. Roadmap to functional cure of chronic hepatitis B: An expert consensus[J]. J Viral Hepat, 2019, 26(10): 1146-1155. DOI: 10.1111/jvh.13126.
[35]	LIU J, WANG T, ZHANG W, et al. Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: A systematic review and meta-analysis[J]. Hepatol Int, 2020, 14(6): 958-972. DOI: 10.1007/s12072-020-10099-x.
[36]	VAILLANT A. REP 2139: Antiviral mechanisms and applications in achieving functional control of HBV and HDV infection[J]. ACS Infect Dis, 2019, 5(5): 675-687. DOI: 10.1021/acsinfecdis.8b00156.
[37]	BAZINET M, PÂNTEA V, PLACINTA G, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naïve to nucleos(t)ide therapy[J]. Gastroenterology, 2020, 158(8): 2180-2194. DOI: 10.1053/j.gastro.2020.02.058.
[38]	YUEN MF, GANE E, KIM DJ, et al. AS069-RO7062931 antisense oligonucleotide phase 1 study demonstrates target engagement in patients with chronic hepatitis B on established nucleos(t)ide therapy[J]. J Hepatol, 2020, 73(Suppl 1): s51. DOI: 10.1016/S0168-8278(20)30648-6.
[39]	GANE E, LOCARNINI S, LIM TH, et al. GS10-Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen supression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment[J]. J Hepatol, 2020, 73(Suppl 1): s20. DOI: 10.1016/S0168-8278(20)30597-3.
[40]	GUPTA SV, FANGET MC, BAKARDJIEV A, et al. SAT462-Pharmacokinetics of VIR-2218, an RNAi therapeutic for the treatment of HBV infection, in healthy volunteers[J]. J Hepatol, 2020, 73(Suppl 1): s885. DOI: 10.1016/S0168-8278(20)32207-8.
[41]	CHEN D, KIM S, BROOKS A, et al. FRI350-Potential biomarkers of response in chronic hepatitis B patients who achieved HBeAg loss upon treatment with toll-like receptor 8 (TLR8) agonist selgantolimod[J]. J Hepatol, 2020, 73(Suppl 1): s571-s572. DOI: 10.1016/S0168-8278(20)31616-0.
[42]	HAGUE RM, HINE D, FERGUSSON J, et al. SAT458 - Immtav, a novel immunotherapy approach to eliminate hepatitis B virus[J]. J Hepatol, 2020, 73(Suppl 1): s882. 10.1016/S0168-8278(20)32203-0. http://www.sciencedirect.com/science/article/pii/S0168827820322030
[43]	WU Y, LIU Y, LU J, et al. Durability of interferon-induced hepatitis B surface antigen seroclearance[J]. Clin Gastroenterol Hepatol, 2020, 18(2): 514-516. e2. DOI: 10.1016/j.cgh.2019.04.020.
[44]	LI MH, YI W, ZHANG L, et al. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy[J]. J Viral Hepat, 2019, 26(Suppl 1): 32-41. DOI: 10.1111/jvh.13151.
[45]	WU Y, WANG X, LIN X, et al. Quantitative of serum hepatitis B core antibody is a potential predictor of recurrence after interferon-induced hepatitis B surface antigen clearance[J]. J Microbiol Immunol Infect, 2021, 54(2): 238-244. DOI: 10.1016/j.jmii.2019.09.004.
[46]	LU FM, WANG J, CHEN XM, et al. The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B[J]. J Chin Hepatol, 2017, 25(2): 105-110. DOI: 10.3760/cma.j.issn.1007-3418.2017.02.005. 鲁凤民, 王杰, 陈香梅, 等. 乙型肝炎病毒RNA病毒样颗粒的发现及其对抗病毒治疗临床实践的潜在影响[J]. 中华肝脏病杂志, 2017, 25(2): 105-110. DOI: 10.3760/cma.j.issn.1007-3418.2017.02.005.